Introduction
Polycystic Ovary Syndrome (PCOS) is a frequent endocrine disorder of unknown etiology a ecting 6 % of premenopausal women ( Franks 1995 , Ehrmann 2005 . Although the clinical expression of the syndrome is highly variable, androgenic e ects constitute the common mechanism responsible for its phenotype. Androgens transport the characteristic features of PCOS, e. g., acne, hirsutism, polyfollicular ovarian morphology and menstrual cycle disorders causing anovulation and infertility ( Gilling-Smith et al. Given the frequency of PCOS, its familial background and variable phenotype, a genetic polymorphism able to modulate the central pathophysiological mechanism stimulated further investigation.
We conducted this study to analyze the infl uence of the CAG repeat polymorphism on the phenotype of women with PCOS.
Subjects and Methods

Patients
Female patients undergoing standardized diagnostics procedures in a university infertility clinic were evaluated regarding their clinical, endocrine and sonographic parameters indicating the presence of PCOS. A PCOS group was defi ned according to the ESHRE/ASRM consensus and compared with a control group not fulfi lling the PCOS criteria ( 
PCOS group
According to the ESHRE/ASRM-consensus, the defi nition of PCOS requires at least 2 of the following 3 criteria: Oligo-or anovulation, clinical or biochemical hyperandrogenism and polycystic ovaries ( The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group 2004 ). In this study, the above criteria were defi ned as follows: Oligo-or anovulation was present in patients with a maximum cycle length > 35 days or a progesterone < 9.54 nmol/l (3 ng/ml) measured on a cycle day [20] [21] [22] [23] [24] 
Laboratory methods
Hormone assays
All hormone assays were performed using commercial kits as part of the clinical routine. 
CAG repeat length
Determination of CAG repeat length was performed as published before ( Zitzmann et al. 2001 ). Briefl y, DNA was extracted from peripheral lymphocytes. CAG repeat length was determined by PCR using specifi c primers, IRD-800 labelling and PAGE ( Zitzmann et al. 2001 ). The number of CAG repeats was analyzed according to the bi-allelic mean, the shorter allele and the longer allele ( Zitzmann et al. 2001 ; Hickey et al. 2002 ) . Patients displaying 2 detected bands of CAG repeat length were considered heterozygous and subject to X-chromosome-inactivation analysis allowing the calculation of an X-weighted biallelic mean ( Hickey et al. 2002 ).
X-chromosome-inactivation assay
Because the AR gene is located on the X-chromosome of which one is inactivated in women, in case of heterozygous CAG repeat alleles the individual X-chromosome-inactivation status is of interest ( Lyon 1992 ; Vottero et al. 1999 ). X-chromosome inactivation correlates with DNA-methylation at the HpaII site near the CAG repeats of exon 1 of the AR gene ( Allen et al. 1992 ). X-chromosome inactivation was assessed as previously described using a methylation sensitive restriction enzyme for pre-digestion ( Hickey et al. 2002 ; Zitzmann et al. 2004 ). The enzyme specifi cally cuts the unmethylated, hence active DNA, leaving all methylated, inactive DNA undigested and available for amplifi cation. To calculate the degree of X-inactivation the signals were analyzed densitometrically and quantifi cation was assessed as described ( 
Statistical analysis
Clinical data and CAG repeat lengths were compared between groups by a Wilcoxon W-test. Comparisons displayed in Table 1 were conducted as an explorative analysis and P -values were not adjusted. The distribution of categorized CAG repeat lengths was analyzed with a Chi 2 -test and calculation of a Somer's d coecient. The correlation of CAG repeat length with cycle length was evaluated using the Spearman Rho coe cient. A one-sided t-test was used to test for random X-chromosome inactivation. In a backwards stepwise binomial regression analysis continuous parameters independently predicting PCOS were identifi ed. Predictors that did not contribute to the model were excluded (exclusion threshold P > 0.04). A P < 0.05 was considered statistically signifi cant. All tests were generated using the statistical software package SPSS (Chicago, IL; release 13.0).
Results
Characterization of patients
Clinical and endocrine patient and control data are displayed in Table 1 . As expected, patients in the PCOS group showed longer cycle intervals, elevated total testosterone, free testosterone and DHEAS serum concentrations, a higher BMI, a higher LH level and a correspondingly elevated LH/FSH ratio. Patients of the PCOS group were 2.5 years younger than controls (P < 0.001). Among PCOS patients, the symptoms of the syndrome were distributed as follows: 61 patients (84.8 %) displayed PCO ovaries, 44 patients (61.2 %) su ered from oligo-/anovulation, 38 patients (52.8 %) had evidence of biochemical hyperandrogenism and 17 patients (23.6 %) were hirsute.
CAG repeat length compared between groups
The length of CAG repeat alleles in all patients followed a normal distribution pattern with a bi-allelic mean of 21.83 alleles, ranging from a minimum of 17 alleles to a maximum of 29 alleles ( Table 1 ). The shortest CAG repeat length observed was 12, the longest 31. Comparing both groups, the bi-allelic mean of PCOS patients was signifi cantly smaller compared with controls (21.43 vs. 21.99, P = 0.031). Analyzing the longer of 2 given CAG repeat alleles, this di erence between groups was confi rmed, the PCOS patients showing a signifi cantly shorter CAG repeat length compared with controls (22.69 vs. 23.75, P = 0.001, Table 1 and Fig. 1 ). In contrast, for the shorter of 2 CAG repeat alleles, no signifi cant di erence between groups was observed. Because the di erence of the bi-allelic mean was caused by the longer CAG repeat allele, further investigations in this study are focused on those alleles. 
CAG repeat length is associated with PCOS
When evaluating the longer of 2 CAG repeat alleles according to 3 categories representing short (< 22), medium (22) (23) (24) (25) and long (> 25) CAG repeat alleles, short alleles, encoding for more active AR, were signifi cantly more frequent in the PCOS group ( P = 0.027, Chi-square Pearson and P = 0.009 Somers-d). Correspondingly, long alleles, protecting from PCOS by encoding for a weaker AR, were more frequent in the control group ( Table 2 ) .
CAG repeat length correlates with cycle length
In PCOS ovaries follicular development is impaired by androgenic e ects resulting in prolonged cycle intervals and accordingly oligomenorrhoea is regarded as a key feature of the syndrome. We investigated cycle intervals as expressed in days to test for an infl uence of the genetic polymorphism on a continuous phenotypic parameter of PCOS. In a non-parametrical test the length of cycle intervals correlated inversely with CAG repeat length of the longer CAG repeat allele ( P = 0.005) and the bi-allelic mean ( P = 0.026), see Table 3 . There was no correlation with other phenotypic traits of PCOS, such as the presence of hirsutism, androgen levels or polycystic ovaries (data not shown).
CAG repeat length as an independent risk factor for PCOS
We then investigated the role of CAG repeat length in context with established risk factors for PCOS. To this end, we included BMI, serum LH, free serum testosterone and CAG repeat length of the longer allele in a backwards stepwise binomial regression analysis and identifi ed the CAG repeat polymorphism as an independent risk factor for PCOS ( P 0.001), Table 4 .
No di erence in X-chromosome inactivation pattern between PCOS and controls
Because mere determination of CAG repeat length cannot give information about the methylation status of the X-chromosome and hence the activity of assessed CAG repeat alleles, in heterozygous patients information about the methylation status is of interest, especially when X-chromosome inactivation does not occur at random but preferably involves the longer or the shorter of 2 given CAG repeat alleles (skewed X-chromosome inactivation) ( Vottero et al. 1999 ). To account for X-chromosome inactivation status, we calculated the X-weighted bi-allelic mean of the CAG repeat alleles ( Hickey et al. 2002 ; Zitzmann et al. 2004 ). The di erence from the bi-allelic mean was calculated, negative values indicating a preferential expression of the shorter CAG repeat allele and positive values indicating a preferential expression of the longer CAG repeat allele. In the whole study population there was no trend to a skewed X-chromosome inactivation, neither in favour of the shorter nor of the longer CAG repeat allele. Analyzing the PCOS group and the control group separately, no skewed X-chromosome inactivation in either of the groups was detected. However, in some individuals a preferential X-chromosome inactivation was present preferring either the longer or the shorter allele ( Fig. 2 ) . In those subjects the assessment of X-chromosome inactivation status might generate genotype-phenotype correlations more precise than the mere number of CAG repeats alone. However, for the whole group, the X-weighted bi-allelic mean yielded correlations of comparable precision to the bi-allelic mean ( Table 1 ) .
Discussion
This study demonstrates an association of the CAG repeat polymorphism of the AR with the phenotype of PCOS. Considering the longer of 2 given alleles, mean CAG repeat allele length was signifi cantly smaller in the PCOS group compared to controls. Furthermore, short CAG repeats were more frequent in PCOS possibly enhancing androgenic e ects in these patients, while longer CAG repeat allele lengths were more frequent in the control group, presumably exerting a protective e ect. Table 4 Short CAG repeat length as an independent risk factor for PCOS. ). Probably because patients were recruited in a reproductive medicine unit, the symptoms most frequent were related to infertility as refl ected by the high incidence of polycystic ovaries and impaired ovulation ( Cussons et al. 2005 ). Accordingly, the fi ndings of our study suggest that the subtile infl uence of the CAG repeat polymorphism could play a role predominantly in PCOS populations not presenting as the fully developed syndrome ( Dewailly et al. 2006 ; Barber et al. 2007 ). Summarized in a unifying hypothesis, these fi ndings are support for a modulating role of the genetic AR polymorphism in PCOS: more active receptors (short CAG repeats) can cause a hyperandrogenic phenotype in absence of markedly elevated androgens while patients with a decreased receptor's activity (long CAG repeats) will develop the disorder preferably in the presence of distinctly elevated androgens. While subgroup analysis according to androgen levels in our PCOS group did not reveal di erences in CAG repeat lengths (data not shown), we report novel evidence that the AR's genetically determined activity was continuously correlated with increased cycle length, a central androgen dependent feature of PCOS. Because it has been shown that enhanced recruitment, prolonged development and premature atresia of follicles are androgen dependent processes contributing to the clinical sequelae of oligomenorrhea and amenorrhea which are regarded as a key feature of the syndrome ( Hillier ( Allen et al. 1992 ). In hirsute patients, preferential X-chromosome inactivation of the shorter allele augmented androgenic e ects ( Vottero et al. 1999 ) and di erent patterns of X-chromosome inactivation accounted for a varying clinical phenotype in sister pairs with PCOS, hinting on an epigenetic etiology of female hyperandrogenism ( Hickey et al. 2006 ). On the contrary, no di erence in X-inactivation pattern was detected in another study on hirsute patients ( Calvo et al. 2000 ) and X-inactivation was not a major determinant in a recent study on PCOS, although a discrete preferential expression of the shorter CAG allele was observed ( Shah et al. 2008 ). In our PCOS population as a whole, preferential X-chromosome inactivation did not play a signifi cant role, but was present in individual subjects. Because X-chromosome inactivation can vary in di erent tissues assessment of inactivation patterns in target tissues such as the ovaries or the skin could help to further elucidate the role of epigenetic processes in di erent conditions of female hyperandrogenism.
Risk factor
Since data collection for this study included patients recruited before the Rotterdam PCOS consensus, we applied a defi nition of polycystic ovarian morphology widely used before, which was not changed throughout the study to preserve consistency ( Adams et al. 1985 ; Polson et al. 1988 ; reviewed in Balen et al. 2003 ). This defi nition requires 10 small follicles instead of the Rotterdam criterion of 12 small follicles ( The Rotterdam ESHRE/ ASRM-sponsored PCOS consensus workshop group 2004 ), the latter treshold identifi ying PCOS with a higher sensitivity and a lower specifi city ( Jonard and Dewailly 2004 ) . In this context, a possible bias on the selection of some PCOS individuals in our study cannot be completely excluded. We conclude that the CAG repeat polymorphism of the AR contributes to the development of a PCOS phenotype, modulating the clinical appearance of the disorder. Our fi ndings are further support for the pivotal role of androgens in PCOS with the genetically determined activity of the AR contributing to central features of the condition: The CAG repeat polymorphism could constitute a factor in the familial background, convey part of the distinct phenotypic variability and transport metabolic consequences of the syndrome.
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